Lead Product(s): RABI-767
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: RABI-767
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding July 14, 2020
The SBIR grant will be used for further development of company's lead therapeutic compound, RABI-767, a novel small molecule lipase inhibitor licensed from the Mayo Foundation for Medical Education and Research.